0001354488-14-001975.txt : 20140418 0001354488-14-001975.hdr.sgml : 20140418 20140418161910 ACCESSION NUMBER: 0001354488-14-001975 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140418 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140418 DATE AS OF CHANGE: 20140418 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 14772254 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 8-K 1 blfs_8k.htm CURRENT REPORT blfs_8k.htm

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

______________________________

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934


April 18, 2014
Date of report (Date of earliest event reported)

____________________________________


BIOLIFE SOLUTIONS, INC.
(Exact Name of Registrant as Specified in Charter)


 
 Delaware  0-18710     94-3076866
 (State or Other Juris- 
diction of Incorporation)   
    (Commission File No.)
 (IRS Employer
Identification No.)
 

3303 Monte Villa Parkway, Bothell, WA 98021
(Address of principal executive offices, including zip code)

(425) 402-1400
(Registrant’s telephone number, including area code)

____________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
 
 
ITEM 7.01.                      REGULATION FD DISCLOSURE.
 
BioLife Solutions, Inc. advises that as of April 18, 2014, it has outstanding 11,941,619 share of common stock, after giving effect to (i) the closing on March 25, 2014 of its public offering of units for gross proceeds of approximately $15.4 million, and the conversion of approximately $14.3 million of indebtedness to its existing noteholders in exchange for units, and (ii) adjustments for fractional shares made through April 18, 2014 with respect to the Company’s January 29, 2014 1:14 reverse stock split.  The number of shares of common stock outstanding remains subject to additional adjustment in accordance with the terms of the reverse stock split.
 
 
ITEM 9.01.                      FINANCIAL STATEMENTS AND EXHIBITS
 
None.
 
 
 
2
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
BIOLIFE SOLUTIONS, INC.
  
       
Date:  April 18, 2014
By:
/s/ Daphne Taylor  
   
Daphne Taylor
  
   
Chief Financial Officer
  
       


3